© Cynthia Turner
Author: Cynthia Turner
Description: Two different molecules (c-MET and EGFR) play multiple key roles in human cancer. a) Both EGFR and c-MET signaling can drive nonsquamous non-small cell lung cancer (nsNSCLC); b) c-MET can compensate for the loss of EGFR signaling, allowing tumors to progress; c) Tivantinib selectively blocks c-MET signaling. When combined with the EGFR inhibitor the two critical cancer-signaling axes can be stopped, halting the progression of nsNSCLC.
Keywords: Airbrush, Color, Three-dimensional / Models, Advertising / Marketing, Editorial, Web, Product Demonstration, Professional Education, Cell biology / Histology, Disease Management, Molecular Biology, Pharmacology